ARID4B and cancer: Considering that the BCKDK inhibitors reduced BCAA levels, we prepared bespoke culture media with lower BCAA concentrations and this also increased sensitivity to paclitaxel, providing a direct demonstration (independent of drug addition) that the reduced BCAA levels increase the sensitivity of cancer cells to paclitaxel.